10:35 AM EST - Acerus Pharmaceuticals Corporation : Reported its financial results for the three-month period ended March 31, 2020. All amounts are in U.S. dollars and are prepared in accordance with International Financial Reporting Standards. Refinancing transactions provide $18 million of new capital to support US growth strategy; $12 million of debt and accrued interest converted to equity. Acerus Pharmaceuticals Corporation
shares T.ASP are trading unchanged at $0.05.
